Triple negative breast cancer (TNBC) does not respond to checkpoint blockade
immunotherapy as a result of immunosuppressive tumor microenvironment. To remodel the …

Immunotherapy gains increasing focus in treating triple‐negative breast cancer (TNBC),
while its efficacy is greatly restricted owing to low tumor immunogenicity and …

Triple-negative breast cancer (TNBC) is an aggressive disease with a high recurrence rate
and poor outcomes in clinic. In this study, inspired by the enriched innate immune cell type …

Triple-negative breast cancer is often aggressive and resistant to various cancer therapies,
especially corresponding targeted drugs. It is shown that targeted delivery of …

Triple-negative breast cancer (TNBC) lacks specific regimens for targeted therapy. Repeat
chemotherapy promotes the evolution of TNBC into highly chemo-resistant tumors that …

Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at
both the pathologic and molecular levels, particularly accelerated aggressiveness, and …

Triple-negative breast cancer (TNBC) is the most metastatic and recurrent subtype of all
breast cancers. Owing to the lack of therapeutic targets, chemotherapy and surgical …

Triple negative breast cancer (TNBC) with poor prognosis and aggressive nature accounts
for 10–20% of all invasive breast cancer (BC) cases and is detected in as much as 15% of …

Despite the remarkable success of immunotherapies over the past decade, their
effectiveness against triple-negative breast cancer (TNBC) is limited to a small subset of …

In the treatment of solid tumors, the complex barriers composed of cancer‐associated
fibroblasts (CAFs) prevent drug delivery and T cells infiltration into tumor tissues. Although …